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Abstract: Pyrrolidine-based iminocyclitols are a promising
class of glycosidase inhibitors. Reported herein is a convenient
epimerization strategy that provides direct access to a range of
stereoisomeric iminocyclitol inhibitors of O-GlcNAcase
(OGA), the enzyme responsible for catalyzing removal of O-
GlcNAc from nucleocytoplasmic proteins. Structural details
regarding the binding of these inhibitors to a bacterial
homologue of OGA reveal the basis for potency. These
compounds are orally available and permeate into rodent
brain to increase O-GlcNAc, and should prove useful tools for
studying the role of OGA in health and disease.
The glycosylation of serine and threonine residues with O-
linked N-acetylglucosamine (O-GlcNAc)[1] is a conserved
protein modification which occurs at high levels in the brains
of eukaryotes.[2] O-GlcNAc is installed by O-GlcNAc trans-
ferase (OGT) and removed by O-GlcNAcase (OGA, a family
GH84 glycoside hydrolase).[3] This modification has been
found to hinder protein phosphorylation, including on the
microtubule-associated protein tau.[4] Notably, the progres-
sion of AlzheimerÏs disease (AD) is closely associated with
hyperphosphorylation and subsequent aggregation of tau,[5]
and decreased levels of O-GlcNAc have been found in the
brains of AD patients.[4c,6] It has also been shown that
O-GlcNAcylation of tau[4c] hinders its phosphorylation and
aggregation in vitro,[6b, 7] thus suggesting a protective role for
this modification. Moreover, maintaining high levels of O-
GlcNAc in the brain by using small-molecule inhibitors of
OGA blocks tau hyperphosphorylation, aggregation, and
neurodegeneration in various transgenic mouse models of
AD.[7, 8] Not surprisingly, the potential to block AD progres-
sion by increasing levels of O-GlcNAc has stimulated interest
in identifying potent, brain penetrant, and selective inhibitors
of OGA.[4d, 9]
Toward this goal, a number of pyrrolidine-based imino-
sugars have demonstrated significant inhibitory activity
toward various glycoside hydrolases,[10] including GH20 b-
hexosaminidases as well as the functionally related GH84
OGA.[11] For example, Wong and co-workers have demon-
strated that the C2-epimeric pyrrolidines 1 and 2 (Figure 1)[12]
are both potent inhibitors of GH20 b-hexosaminidases (b-
Hex), and the structurally related iminocyclitol 3, as well as
the configurationally unique reverse amides 4 and 5, and
analogues, have appeared in the patent literature as inhibitors
of OGA.[11d] Considering the profound effects iminocyclitol
configuration has on both the potency and selectivity of these
glycoside hydrolase inhibitors, access to stereoisomers and an
improved understanding of their binding interactions with
OGA is critical to advancing this class of inhibitor for
treatment of AD.
Despite significant therapeutic potential, the synthesis of
polyhydroxypyrrolidine iminosugars is often complicated by
a reliance on carbohydrate starting materials and elaborate
protecting/functional-group interconversion strate-
gies.[10b, 13, 14] These challenges are manifested in the synthesis
of configurationally distinct iminocyclitols (e.g., 2, 4, and 5),
where each target requires a unique carbohydrate building
block. Recently, we reported a convenient two-step iminocy-
clitol synthesis (see inset, Scheme 1) and demonstrated this
process in the preparation of a small library of imino C-
nucleoside analogues.[15] Given the notable activity of the
iminocyclitols 4 and 5 as OGA inhibitors, we were interested
in adapting this synthesis for the preparation of related
iminocyclitols possessing the relative stereochemistry of the
general structure 9. Moreover, we envisioned that a series of
retro-Michael (rM) hetero-Michael (hM) reactions involving
9 could be stereochemically tuneable through deliberate
Figure 1. Structures of iminocyclitol OGA and b-HEX inhibitors.
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choice of the acyl group, and thus afford access to diastereo-
mers at both C2 and C3 to probe the relationship between
stereochemistry and OGA inhibition. For example, rM
reaction of amides or esters (e.g., 9, X = OR/NR2) could
lead sequentially to the enoate 10 and furanone 14. A
subsequent hM reaction through the equilibrating and
epimeric furanone 15, in which the furanone is situated
pseudo-equatorially, would afford the lactone 16 and ulti-
mately the C3-epimeric iminocyclitol 17. Alternatively,
a rMhM reaction involving the corresponding aldehyde
(e.g., 9, X = H) should lead to an equilibrating mixture of
2S and 2R epimers 9 and 11, respectively.[16] As only the 2,3-
cis-configured diastereomer 11 is capable of forming the
hemiacetal 12, this process would provide straightforward
access to the C2 epimeric iminocyclitol 13. Here we report
concise syntheses of a series of novel polyhydroxypyrrolidinyl
acetamides through the realization of these two complemen-
tary rMhM epimerization strategies. By exploiting this con-
venient process we also report on a potent, selective, and
brain penetrant OGA inhibitor.
As outlined in Scheme 2, exploiting our one-pot proline-
catalyzed a-chlorination DKR aldol reaction[17] with the
readily available aldehydes 18a and 18b,[18] we first targeted
the functionalized iminoribitol 21. Despite the potential for b-
elimination, each of these reactions afforded the expected
syn-chlorohydrin as the major product in good yield, diaste-
reoselectivity, and enantioselectivity. While reductive amina-
tion of the aldol adduct 19a did not lead directly to the
iminoribitol 21, the intermediate amino chlorohydrin 20 could
be readily cyclized by simply heating in toluene with
NaHCO3.
[15] Removal of both the acetonide and Boc protect-
ing groups required brief treatment with acid and delivered 21
in excellent overall yield. Though this remarkably efficient
(four-step) synthesis of 21 could be readily adapted for the
preparation of structural analogues for medicinal chemistry
purposes, this diastereomer proved to be a weak inhibitor of
human OGA (hOGA) with a Ki value of 890 mm (see the
Supporting Information).
We therefore investigated the rMhM reaction sequence,
shown in Scheme 1, in an effort to access the corresponding
3R-diastereomer 25. Unfortunately, under a variety of
reaction conditions, 21 proved incapable of engaging in rM
reactions. Anticipating that the increased acidity of the a-
protons in the corresponding ester would improve the like-
lihood of rM processes, we targeted the equivalent polyhy-
droxypyrrolidinyl acetate. As detailed in Scheme 2, we were
delighted to find that reductive amination of ester 19b and
subsequent heating in MeOH resulted directly in the for-
mation of the lactone 24, in which the C3 stereocenter had
been inverted relative to that in 21. The selective formation of
24 and realization of this unique C3-epimerization process
presumably involves formation of rapidly equilibrating fur-
anone diastereomers (e.g., 14 and 15 ; Scheme 1). The
subsequent hM reaction then occurs through a pseudo-chair
conformation in which the furanone is situated pseudo-
equatorially with respect to the forming pyrrolidine. Notably,
small amounts of the C2/C3-bis-epimeric lactone (not shown),
presumably derived from cyclization through a pseudo-axially
oriented furanone (e.g., 14, Scheme 1), were also produced in
this reaction (d.r. 12:1). However, when purified samples of
these lactones were re-subjected to the reaction conditions
neither underwent further epimerization, thus indicating
a kinetic preference for the formation of 24. Exploiting this
facile C3-epimerization strategy, 25 was made readily avail-
Scheme 1. A two-step synthesis of ribose-configured iminocyclitols 8
and a unified strategy to access the C2/C3 stereoisomeric iminocycli-
tols 13 and 17.
Scheme 2. Synthesis of the C3-epimeric iminocyclitols 21 and 25.
Reaction conditions: a) 6, NCS, (S)-proline, CH2Cl2, RT, 24 h (55%);
b) n-pentylamine, AcOH, THF, RT, 1 h then NaB(CN)H3, 1 h (78%);
c) 1. NaHCO3, PhMe, 105 8C, 24 h, (54%); 2. MeOH, TFA/CH2Cl2
(1:1), RT, 1 h (79%); d) MeOH, 120 8C, 4 h (55%); e) MeNH2 (40% in
H2O), RT, 1 h (88%). Boc= tert-butoxycarbonyl, NCS =N-chloro-
succinimide, TFA = trifluoroacetic acid.
able in four steps from the aldehyde 19 b. Notably, the 2S-
epimer 25 proved to be a significantly improved inhibitor of
hOGA when compared with 21, exhibiting a Ki value of 14(
3) mm.
Finally, we targeted the aldehyde 29 as an intermediate
that could be used to explore the C2-epimerization strategy
outlined in Scheme 1. Toward this goal, reductive amination
of the ketochlorohydrin 26 (available in one step from 4-
Further, we sought to understand the molecular basis for
the discrepancy in potencies observed toward hOGA by
obtaining structures of several of these compounds bound to
the active site of a GH84 homologue of hOGA from the
bacterium Bacteroides thetaiotamicron. This enzyme,
BtGH84, is capable of removing O-GlcNAc from modified
proteins and has an active site which comprises residues which
are conserved with hOGA.[19] Structures, obtained by soaking
several of these compounds into apo-crystals of BtGH84,
revealed the critical interactions for each diastereomer
(Figure 3). For binding of all the compounds, movements of
amino-acid side-chains or the main chain are not observed,
thus indicating a rigid active site which avoids compensatory
changes on protein geometry to accommodate the different
stereochemistry of the inhibitors. All four compounds formed
a network of multiple interactions with BtGH84. However,
Figure 2. The iminocyclitols 32–34 and their inhibitory activity towards
hOGA.
Figure 3. Structural analysis of a series of OGA inhibitors in complex with the hOGA homologue
BtGH84. A) Iminocyclitol 21. B) Iminocyclitol 25. C) Iminocyclitol 31. D) Iminocyclitol 34. The
enzyme is shown in beige, the ligand is shown in yellow, and hydrogen bonds are indicated by
dashed black lines. The length of the hydrogen bonds may contribute to the differences in
affinity.
Scheme 3. Synthesis of the C2-epimeric iminocyclitol 31. Reaction
conditions: a) n-pentylamine, AcOH, THF, RT, 1 h then NaB(CN)H3,
1 h (87%); b) NaHCO3, PhMe, 105 8C, 24 h (88%); c) 1. AD-mix-b,
acetone/H2O (1:1), 4 8C, 24 h; 2. NaIO4, EtOH/H2O (2:1), RT, 1 h,
d) silica gel, CHCl3, RT, 16 h (62% from 28) e) TEMPO, DIB, CH2Cl2,
RT, 16 h (66%); f) HCl (cat.), MeOH, RT, 1 h then MeNH2 (40 wt% in
H2O), RT, 1 h (95%). DIB = (diacetoxyiodo)benzene, TEMPO= 2,2,6,6-
tetramethyl-1-piperidinyloxyl, THF = tetrahydrofuran.
pentenal)[17] afforded the aminochloro-
hydrin 27, which was cyclized to the 
pyrrolidine 28 after brief heating in 
toluene with NaHCO3 (Scheme 3). The 
required aldehyde 29 was readily 
accessed by oxidative cleavage of the 
alkene function in 28. We were 
delighted then to find that simply 
exposing 29 to silica gel in chloro-
form[16] resulted in complete conversion 
into the C2-epimeric lactol 30. Conver-
sion of this latter material into the 
amide 31 then involved a straightfor-
ward sequence of reactions including 
oxidation to the corresponding lactone 
and brief exposure to acid and then 
methylamine. The iminocyclitol 31 
proved to be a potent inhibitor of 
OGA with a Ki value of 1.7( 0.3) nm.
With concise synthetic routes to 21, 
25, and 31 established, we rapidly 
assembled a small collection of ana-
logues (32–34 ; see the Supporting 
Information for details). As summar-
ized in Figure 2, the most potent inhib-
itors of hOGA among this series of 
stereoisomeric iminocyclitols are the 
(2R,3S)-configured congeners 31 and 
34.
relative stereochemistry was a critical determinant of hydro-
gen-bond lengths. For example, in the complex with 21 (2S,3S-
configuration), the position of the N-acyl moiety leads to
three close contacts, two with D344 and one with the main
chain oxygen atom of G135. This position potentially yields
more repulsive interactions between the protein and the
inhibitor. Better hydrogen-bond geometry was observed for
25 (2S,3R-configuration) primarily reflecting improved inter-
actions between the 3R-hydroxy group and the carbonyl of
G135. In the complex with 31 and 34 all hydrogen bonds
adopt nearly optimal geometries in respect to their length and
angle, thus explaining the high affinity of both compounds.
Such variations in binding of diastereomeric diol inhibitors
were also observed for HIV-1 protease, where a repulsive
interaction between a hydroxy group and the carbonyl of
a glycine was noted.[20]
Given the potency of the (2R,3S)-configured iminocycli-
tols, we were interested in evaluating the potential value of
such compounds in vivo. Further, considering the potent
inhibition of hOGA in cells by PUGNAc[21] and GlcNAcstatin
C,[9d] both of which bear a phenyl moiety positioned several
atoms away from the pseudo-sugar ring, we selected 34
(Figure 2) for further studies [Ki = 9( 2) nm]. As depicted in
Figure 3 (panel D), the X-ray structure of 34 complexed with
BtGH84 is consistent with that of the configurationally
related 31. We next determined the pharmacokinetic proper-
ties of 34 in plasma and brains of mice and found it shows
good bioavailability and distribution as well as ability to cross
the blood-brain-barrier (see Figures S1 and S2 in the Sup-
porting Information) Analysis of sagittal brain tissue sections
obtained from mice at various times following oral dosing by
gavage reveals that O-GlcNAc levels are qualitatively
increased within the brain in various regions, including
cortex and hippocampus, as compared to control mice
(Figure 4). Immunoblot analysis of mouse brain tissue
homogenates obtained from mice 16 hours post dosing with
34 shows quantitative increases in O-GlcNAc levels within
brain (Figure 4).
In summary, we describe a unique and convenient
synthetic approach to access a series of diastereomeric
pyrrolidine iminocylitol inhibitors of hOGA. The most
potent of these compounds are single-digit nanomolar
inhibitors of hOGA. Structural analysis of selected diaste-
reomers in complex with the bacterial hOGA homologue,
BtGH84, revealed critical hydrogen bonds engaging D344
and G135, and offer a rationale for the preference for the
(2R,3S)-configured iminocyclitols 31 and 34. Furthermore, we
found a member among this class of compounds to be both
orally bioavailable and brain penetrant in mice, with treat-
ment leading to sustained increases in global O-GlcNAcyla-
tion. Given the ease of synthetic access to significant
quantities of 34, we anticipate that 34 may prove to be
a useful research tool for probing the functional role of O-
GlcNAc in vivo, including within the brain. Further, the
ability to access diastereomeric pyrrolidines may be useful for
the study of other glycoside hydrolases and structural
variation could also enable the identification of still more
potent compounds having significantly improved properties.
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